Earlier this week, Elon Musk announced his brain-computer interface company, Neuralink, implanted a device in a human for the first time. The company’s PRIME study, approved by the U.S. Food and Drug Administration last year, is testing a brain implant for “people with paralysis to control external devices with their thoughts.”
In the past few years, Neuralink has . Nevertheless, the PRIME trial is a significant milestone for a company less than 10 years old.
However, Neuralink’s challenges are far from over. Implanting a device is just the beginning of a decades-long clinical project beset with competitors, financial hurdles, and ethical quandaries.
Decades of development
The first reported demonstration of a brain-computer interface occurred in 1963. During a lecture at the University of Oxford, neuroscientist William Grey Walter bewildered his audience by linking one of his patient’s brains to the projector, where they advanced the slides of his presentation using only their thoughts.
However, the current wave of exploration in using brain-recording techniques to restore movement and communication to patients with severe paralysis began in the early 2000s. It draws on studies from the 1940s that measured the activity of single neurons, and more complex experiments on rats and monkeys in the 1990s.
Neuralink’s technology belongs to the next generation of recording devices. These have multiple electrodes, greater precision, and are safer, longer-lasting, and more compatible with the body. The Neuralink implant is thinner, smaller, and less intrusive than the “Utah array” device, widely used in existing brain-computer interfaces, which has been available since 2005.
Neuralink’s device is implanted by a special robot that rapidly inserts polymer threads, each containing dozens of electrodes. In total, the device has 3,072 electrodes — dwarfing the 100 electrodes of the Utah array.
Competitors to Neuralink
Neuralink faces stiff competition to commercialize the first next-generation brain-computer interface.
Arguably, its fiercest competitor is an Australian company called Synchron. This Melbourne-based start-up recently used a microelectrode mesh threaded through the brain’s blood vessels. This allowed paralyzed patients to use tablets and smartphones, surf the Internet, send emails, manage finances (and post on X, formerly Twitter).
The Synchron implant is described as a “minimally invasive” brain-computer interface. It requires only a minor incision in the neck, rather than the elaborate neurosurgery required by Neuralink and most other brain-computer interfaces.
In 2021, Synchron received a “Breakthrough Device Designation” in the United States and is now on to its third clinical trial.
Patient welfare
This competitive landscape raises potential ethical issues concerning the welfare of patients in the PRIME study. For one, recruiting participants to neural implant studies is notoriously difficult. Patients must meet strict criteria to be eligible, and the trials are inherently risky and ask a lot of participants.
Musk’s public profile may help Neuralink find and enroll suitable patients. However, the company must be prepared to provide patients long-term support (potentially decades). If things go wrong, patients may need support to live with the consequences; if things go right, Neuralink may need to ensure the devices don’t stop working.
In 2022, a company called Second Sight Medical Product demonstrated the risks. Second Sight made retinal implants to treat blindness. When the company went bankrupt, it left more than 350 patients around the world with obsolete implants and no way to remove them.
If Neuralink’s devices succeed, they will likely transform patients’ lives. What happens if the company winds up operations because it can’t make a profit? A plan for long-term care is essential.
What’s more, the considerable hype surrounding Neuralink may have implications for obtaining informed consent from potential participants.
Musk famously compared the implant to a “Fitbit in your skull.” The device itself, Musk recently revealed, is misleadingly named “Telepathy.”
This techno-futurist language may give participants unrealistic expectations about the likelihood and kind of individual benefit. They may also underappreciate the risks, which could include severe brain damage.
The way forward
In this next chapter of the Neuralink odyssey, Musk and his team must strongly commit to research integrity and patient care. Neuralink’s establishing a patient registry to connect with patient communities is a step in the right direction.
Long-term planning and careful use of language will be necessary to prevent harm to patients and families.
The nightmare scenario for all neurotechnology research would be a repeat of Walter Freeman’s disastrous pre-frontal lobotomy experiments in the 1940s and 1950s. These had catastrophic consequences for patients and set research back by generations.
Nathan Higgins, Ph.D. candidate in Psychology, Monash University
This article is republished from The Conversation under a Creative Commons license. Read the original article.
